At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 24 enrolled
Drug / intervention
Simvastatindrug
Likely dose
Simvastatin 40 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 2 Study of Simvastatin Treatment Effects on Vaso-occlusive Pain in Sickle Cell Disease
In Brief
A Phase 2 clinical trial evaluating Simvastatin for Sickle Cell Disease. Completed, enrolled 24 participants across 1 site.
Detailed Summary
The purpose of this study is to determine whether simvastatin is effective in reducing the frequency and intensity of vaso-occlusive pain episodes in patients with sickle cell disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSickle Cell Disease
CountriesUnited States
CollaboratorsUniversity of California, Los Angeles
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2012
First PostedOct 2012
Primary CompletionMay 2015
Study CompletionJun 2015
TodayJul 2026
First PostedOct 8, 2012
Enrollment StartFeb 1, 2012
Primary CompletionMay 1, 2015
Study CompletionJun 1, 2015
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 13.7 years ago
Interventions
Simvastatindrug
40 mg, orally, once daily for 3 months